AI alliance to redefine the future of ageing and therapeutics
Juvenescence - 16-Apr-2025M42 and Juvenescence join forces to accelerate precision medicine and longevity
Juvenescence
Developing therapies against different aging related diseases.
Juvenescence is a bio-pharma development company developing therapies focused on allowing people worldwide to live longer, healthier lives. We have raised USD $65M to build an ecosystem and pipeline of assets targeting ageing, age-related disease and regeneration.
Visit website: https://www.juvlabs.com/
Details last updated 04-May-2019
Juvenescence News
Reason reports back from Age-Related Disease Therapeutics Summit 2023
Fight Aging! - 16-Jun-2023Many people believe lots of clinical trials of novel therapeutics targeting mechanisms of aging will start up in the next few years
Summary of Jim Mellon presentation at Longevity Med Summit
Live Forever Club - 19-May-2023Urges individuals with resources and a desire to contribute positively to humanity to invest in the longevity industry
AgeX credit running out with substantial doubt it can continue
FierceBiotech - 15-Aug-2022Let's hope their research is either successful for the company or its successors
JuvLife Division raises 3.7 million euros for making antiaging product with Chrysea
Longevity Technology - 13-Jun-2022Metabolites induce autophagy, stimulate cellular regeneration for healthy ageing
Display all news
Juvenescence is also referenced in the following:
Selah Therapeutics
Company focused on novel ketone-based therapies for the treatment of heart diseases
Juvenescence Creations
Investing in the Future of Longevity – the Ketone Chapter
10-May-2022
Juvenescence webinar about the latest research and developments on future of longevity investment
People at Juvenescence
Jim Mellon
British entrepreneur, author and philanthropist with interests across a number of industries
Topics mentioned on this page:
Ageing Research
